Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00205790 · ClinicalTrials.gov registry record · NA

GORE-TEX PROPATEN Vascular Graft Study

A NA study of Peripheral Vascular Diseases, sponsored by W.L.Gore & Associates.

Completed
Registry status
NA
Development phase
200
Enrollment target
18
Study locations

NCT00205790: Completed NA study of Peripheral Vascular Diseases, sponsored by W.L.Gore & Associates.

NCT00205790 is a NA study of Peripheral Vascular Diseases that has completed, run by W.L.Gore & Associates. The registered enrollment target is 200 participants, below the 486-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (59% lower). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00205790, a NA study of Peripheral Vascular Diseases, has completed, sponsored by W.L.Gore & Associates.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target
18
Study locations

Study Summary

To demonstrate equivalence in patency performance of GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts in a peripheral bypass application to support a claim of substantial equivalence.

Interventions

  • DEVICE Vascular graft

Study Locations (18)

Florida

  • Memorial Regional Hospital - Hollywood
  • St. Vincent's Hospital - Jacksonville
  • Sacred Heart Hospital - Pensacola

Massachusetts

  • Baystate Medical Center - Springfield
  • Mercy Medical Center - Springfield

Michigan

  • William Beaumont Hospital - Bingham Farms
  • Borgess Hospital - Kalamazoo

District of Columbia

  • Georgetown University Hospital - Washington D.C.

Georgia

  • Medical Center of Central Georgia - Macon

Kentucky

  • Jewish Hospital - Louisville

Maryland

  • Upper Chesapeake Medical Center - Baltimore

Mississippi

  • University of Mississippi Medical Center - Jackson

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2003-02
Est. Completion 2007-08
Phase NA
W.L.Gore & Associates

53 total trials

What the finished NCT00205790 record still lists

NCT00205790 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (59% lower).

The record links to 1 condition, with Peripheral Vascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Vascular graft is the first listed.

NCT00205790 lists 18 locations in 14 states (Florida, Massachusetts, Michigan).

Frequently Asked Questions

What is clinical trial NCT00205790 about?

NCT00205790 is a clinical study titled "GORE-TEX PROPATEN Vascular Graft Study". To demonstrate equivalence in patency performance of GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts in a peripheral bypass application to support a claim of substantial equivalence.

What is the current status of trial NCT00205790?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2003-02. Estimated completion is 2007-08.

What conditions does trial NCT00205790 study?

This clinical trial studies the following conditions: Peripheral Vascular Diseases.

What interventions are being tested in trial NCT00205790?

The interventions under investigation include: Vascular graft (DEVICE).

Who is sponsoring clinical trial NCT00205790?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00205790 being conducted?

This trial has 18 study locations across District of Columbia, Florida, Georgia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Vascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00205790's enrollment target sits among peer trials

200 10th of 19 higher than 10 of 19 other Peripheral Vascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Vascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00205790, the US trial registry maintained by the National Library of Medicine. NCT00205790 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.